CN111148519A - 制备寡核苷酸化合物的方法 - Google Patents

制备寡核苷酸化合物的方法 Download PDF

Info

Publication number
CN111148519A
CN111148519A CN201880062621.9A CN201880062621A CN111148519A CN 111148519 A CN111148519 A CN 111148519A CN 201880062621 A CN201880062621 A CN 201880062621A CN 111148519 A CN111148519 A CN 111148519A
Authority
CN
China
Prior art keywords
oligonucleotide
composition
certain embodiments
000mmol
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880062621.9A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼·弗兰克
凯文·克洛普弗
小唐纳德·约瑟夫·加拉格尔
拉蕾·贾法普尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN111148519A publication Critical patent/CN111148519A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880062621.9A 2017-07-28 2018-07-26 制备寡核苷酸化合物的方法 Pending CN111148519A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538504P 2017-07-28 2017-07-28
US62/538,504 2017-07-28
PCT/US2018/043867 WO2019023439A1 (en) 2017-07-28 2018-07-26 PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDE COMPOUNDS

Publications (1)

Publication Number Publication Date
CN111148519A true CN111148519A (zh) 2020-05-12

Family

ID=65041406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880062621.9A Pending CN111148519A (zh) 2017-07-28 2018-07-26 制备寡核苷酸化合物的方法

Country Status (6)

Country Link
US (1) US20200392491A1 (enExample)
EP (1) EP3658155A4 (enExample)
JP (1) JP2020528910A (enExample)
KR (1) KR20200042902A (enExample)
CN (1) CN111148519A (enExample)
WO (1) WO2019023439A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110468171A (zh) * 2019-09-20 2019-11-19 凯莱英医药集团（天津）股份有限公司 核酸的合成方法
CN117143165A (zh) * 2023-08-30 2023-12-01 上海奥锐特生物科技有限公司 一种寡核苷酸的纯化方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505598A (ja) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
WO2020173845A1 (en) * 2019-02-26 2020-09-03 Roche Innovation Center Copenhagen A/S Oligonucleotide formulation method
JP7311642B2 (ja) * 2019-07-09 2023-07-19 エフ． ホフマン－ラ ロシュ アーゲー オリゴヌクレオチドを脱保護するための方法
KR20220156843A (ko) * 2020-02-21 2022-11-28 바이오젠 엠에이 인코포레이티드 한외여과 / 정용여과를 사용한 올리고뉴클레오티드 조성물의 제조 방법
WO2024138152A1 (en) * 2022-12-23 2024-06-27 Asahi Kasei Bioprocess America, Inc. System for performing cleavage, deprotection, ultrafiltration, and diafiltration operations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050789A2 (en) * 2005-10-25 2007-05-03 Nëdken Corporation Glycosyl-oligonucleotide conjugates and methods
WO2014120861A2 (en) * 2013-01-31 2014-08-07 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
WO2017055611A2 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
CN106573065A (zh) * 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532982A (ja) * 2014-10-17 2017-11-09 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７アンチセンスオリゴヌクレオチドの同位体置換体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050789A2 (en) * 2005-10-25 2007-05-03 Nëdken Corporation Glycosyl-oligonucleotide conjugates and methods
WO2014120861A2 (en) * 2013-01-31 2014-08-07 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
CN106573065A (zh) * 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
WO2017055611A2 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110468171A (zh) * 2019-09-20 2019-11-19 凯莱英医药集团（天津）股份有限公司 核酸的合成方法
CN110468171B (zh) * 2019-09-20 2021-10-29 凯莱英医药集团（天津）股份有限公司 核酸的合成方法
CN117143165A (zh) * 2023-08-30 2023-12-01 上海奥锐特生物科技有限公司 一种寡核苷酸的纯化方法

Also Published As

Publication number Publication date
EP3658155A4 (en) 2021-06-30
US20200392491A1 (en) 2020-12-17
WO2019023439A1 (en) 2019-01-31
KR20200042902A (ko) 2020-04-24
JP2020528910A (ja) 2020-10-01
EP3658155A1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
CN111148519A (zh) 制备寡核苷酸化合物的方法
JP7478210B2 (ja) 修飾オリゴヌクレオチド及び使用方法
TW201639962A (zh) Ｒｎａ干擾劑
US20180162897A1 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
US11939581B2 (en) Methods and compositions for targeting PD-L1
EA008741B1 (ru) Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
WO2015011694A2 (en) Isotopologues of smad7 antisense oligonucleotides
CN1118140A (zh) 为提高在酸性pH的稳定性而改性的低聚核苷酸
JP2022168017A (ja) 多価カチオン塩組成物を用いたポリヌクレオチド調製方法
US9249178B2 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
US20210269797A1 (en) Methods and compositions for targeting pd-l1
JPH07501314A (ja) ３′−末端封鎖されたオリゴヌクレオチド
CN111321159B (zh) 用于免疫调节的嵌合核酸分子及其应用
WO2021039879A1 (ja) 胃癌分子標的核酸医薬
JP7707184B2 (ja) 修飾短干渉ｒｎａ組成物、及びがんの処置におけるそれらの使用
JP2024541701A (ja) 治療剤としての環状構造化オリゴヌクレオチド
TW202019944A (zh) 含有三硫代磷酸酯核苷間連接之寡核苷酸
JPH0834737A (ja) 新規抗ｈｉｖ剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200810

Address after: Ai Erlandubailin

Applicant after: Nogra Pharma Ltd.

Address before: New jersey, USA

Applicant before: CELGENE Corp.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200512

WD01 Invention patent application deemed withdrawn after publication